3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets , the market could be worth about $10.6 billion from $5.3 billion in 2023. With it, we can remove cells from the body, edit them and reintroduce them back into the body. All in an effort to help treat sickle-cell anemia, cancers, blood disorders, blindness, cystic fibrosis and even muscular dystrophy. Months ago, CRISPR Therapeutics (NASDAQ: CRSP ) received Food & Drug Administration approval for its sickle-cell treatment. It also received clearance for its gene-edited therapy for transfusion-dependent beta-thalassemia (TDT). Even more exciting, generative artificial intelligence (AI) has made its way into gene editing. Profluent , an AI-first protein design company, just introduced OpenCRISPR, an AI-generated gene editor. “Our success points to a future where AI precisely designs what is needed to create a range of bespoke cures for disease. To spur innovation and democratization in gene editing, with the goal of pulling this future forward, we are open-sourcing the products of this initiative,” said Ali Madani, Profluent co-founder and CEO, as quoted by Fierce Biotech ....

InvestorPlace - 5/2/2024 6:04:00 AM More News for ILMN
Stock Analysis for ILMN
Related Stocks: ILU-GF,ILU-GM,ILU-GY,ILU-GS,ILU-GI,ILU-GD,ILU-GB,0J8Z-LN,ILMN,0JBU-LN,NTLA,CRSP,CRSP,SSTK,0A8F-LN,TXG,GNOM,GNOM-MM,GX0D-GB,MGX